Brookline Capital Acquisition Increases Veru (NASDAQ:VERU) Price Target to $31.00

Veru (NASDAQ:VERUGet Rating) had its price target lifted by analysts at Brookline Capital Acquisition from $29.00 to $31.00 in a note issued to investors on Wednesday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the stock. Brookline Capital Acquisition’s price objective would suggest a potential upside of 114.53% from the company’s previous close.

A number of other equities analysts have also weighed in on VERU. Oppenheimer boosted their price target on shares of Veru from $25.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 12th. TheStreet raised shares of Veru from a “d+” rating to a “c” rating in a research note on Friday, April 29th. Zacks Investment Research cut shares of Veru from a “buy” rating to a “hold” rating in a report on Thursday, April 21st. Jefferies Financial Group increased their price target on shares of Veru from $33.00 to $55.00 in a research note on Friday, May 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Veru in a research note on Friday, May 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $32.17.

Shares of Veru stock traded down $1.15 during trading on Wednesday, hitting $14.45. 567,894 shares of the company’s stock were exchanged, compared to its average volume of 22,628,762. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -42.38 and a beta of -0.58. The business has a 50-day simple moving average of $8.54 and a 200-day simple moving average of $7.14. Veru has a 52-week low of $4.34 and a 52-week high of $17.50.

Veru (NASDAQ:VERUGet Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.02). Veru had a negative net margin of 45.56% and a negative return on equity of 18.64%. During the same quarter last year, the business posted ($0.04) EPS. Sell-side analysts forecast that Veru will post -0.52 EPS for the current year.

A number of institutional investors have recently made changes to their positions in VERU. BlackRock Inc. grew its stake in Veru by 3.8% in the 3rd quarter. BlackRock Inc. now owns 4,237,483 shares of the company’s stock valued at $36,146,000 after acquiring an additional 154,862 shares during the last quarter. Vanguard Group Inc. grew its stake in Veru by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 3,149,286 shares of the company’s stock valued at $15,212,000 after acquiring an additional 119,891 shares during the last quarter. State Street Corp grew its stake in Veru by 7.5% in the 1st quarter. State Street Corp now owns 1,163,926 shares of the company’s stock valued at $5,622,000 after acquiring an additional 80,978 shares during the last quarter. Geode Capital Management LLC grew its stake in Veru by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 1,083,324 shares of the company’s stock valued at $6,380,000 after acquiring an additional 14,144 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its stake in Veru by 9.3% in the 4th quarter. Nuveen Asset Management LLC now owns 807,839 shares of the company’s stock valued at $4,758,000 after acquiring an additional 68,520 shares during the last quarter. Institutional investors own 29.11% of the company’s stock.

About Veru (Get Rating)

Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.

Read More

Stock Target Advisor logo

Analyst Recommendations for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.